Clinical trial
Efficacy and Safety of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients Receiving Rifampicin Based Anti-TB Therapy
NCT04513379 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients Receiving Rifampicin Based Anti-TB Therapy
- Lead sponsor
- Shanghai Public Health Clinical Center
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- November 1, 2020
- Completion date
- January 31, 2023
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.